Here are a few brief analogies for PDS Biotechnology (PDSB):

1. A Moderna for T-cell activating cancer therapies.

2. A younger Merck, but solely focused on developing innovative T-cell based cancer immunotherapies.

3. An early-stage Regeneron, but specialized in T-cell activating cancer treatments.

• VERSAMUNE® Platform: A proprietary T-cell activating technology that forms the basis for their investigational immunotherapies and vaccines.
• PDS0101: Their lead investigational immunotherapy for human papillomavirus (HPV)-associated cancers, developed using the VERSAMUNE® platform.

PDS Biotechnology (PDSB) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. As a clinical-stage company, it does not currently have commercial products on the market sold to individuals or directly to healthcare providers. Instead, its business model involves research and development, funded primarily through equity financing, grants, and strategic collaborations.

Therefore, PDS Biotechnology sells primarily to other companies and organizations through collaborations and partnerships, rather than to individual customers. Based on their latest financial reports and company disclosures, PDS Biotechnology's major collaborators and sources of revenue (acting as "customers" in the context of their business model) include:

• Merck & Co., Inc. (Symbol: MRK): PDS Biotechnology has a significant clinical collaboration agreement with Merck to evaluate its lead product candidate, PDS0101, in combination with Merck's KEYTRUDA® (pembrolizumab) in multiple clinical trials. This collaboration can involve milestone payments and other financial contributions from Merck, alongside shared development efforts.
• The National Cancer Institute (NCI): PDS Biotechnology has research collaboration agreements and receives grants from the NCI, which is part of the National Institutes of Health (NIH), a U.S. government agency. The NCI does not have a public stock symbol.

The clear emerging threat to PDS Biotechnology (PDSB) is the advancement and potential market entry of highly efficacious T-cell receptor (TCR) therapies and other adoptive cell therapies (ACTs) specifically targeting human papillomavirus (HPV)-associated cancers.

PDSB's lead candidate, PDS0101 (VERSAMUNE®), is a therapeutic vaccine designed to activate the immune system against HPV-infected cancer cells. However, TCR therapies, which involve engineering a patient's own T-cells to specifically recognize and kill cancer cells expressing HPV antigens (such as E6 and E7), represent a distinct and potentially more potent therapeutic modality.

Companies and research institutions are actively developing and testing TCR therapies for solid tumors, with specific efforts targeting viral-associated cancers, including those driven by HPV. If these advanced cell therapies demonstrate significantly superior clinical efficacy, durability, or safety profiles compared to PDSB's immunotherapy approach in ongoing or future clinical trials, they could offer a more effective treatment paradigm and capture a substantial portion of the market for HPV-associated cancers, thereby threatening PDSB's primary pipeline.

The addressable markets for PDS Biotechnology's main products are as follows:

PDS0101 (Versamune® HPV)

PDS0101 targets HPV16-positive cancers, specifically recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) and HPV+ Oropharyngeal Cancer (OPSCC).

• The global head and neck squamous cell carcinoma market is projected to reach approximately $6.2 billion by 2029.
• The U.S. market potential for PDS0101 (Versamune® HPV) is estimated to be $2-3 billion.
• The market size for HPV+ oropharyngeal cancer in the leading markets (U.S., EU4 countries, U.K., and Japan) is expected to grow significantly by 2034, with the U.S. accounting for the highest market size in 2024.
• Global revenue for PDS-0101 is forecast to reach an annual total of $197 million by 2038.

PDS0103 (Versamune® MUC1)

PDS0103 targets MUC1-positive cancers, including ovarian, breast, colorectal, and lung cancers. The specific addressable market size for MUC1-positive cancers for this product is not explicitly available in the provided information. Therefore, the market size for this product is null.

PDS Biotechnology (PDSB) is a clinical-stage biopharmaceutical company, and as such, it is not currently generating revenue. Expected future revenue growth over the next 2-3 years will be driven primarily by the successful advancement and potential commercialization of its product pipeline. The key drivers include:

1. Advancement and Potential Commercialization of PDS0101 (Versamune HPV) for HPV16-Positive Cancers: PDS0101 is the company's lead immunotherapy candidate, which is in a Phase 3 clinical trial (VERSATILE-003) for first-line recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma. Positive updated data from the VERSATILE-002 trial has shown a durable clinical benefit and median overall survival, indicating significant potential. The final data readout for the VERSAL-two trial is anticipated by the end of 2025 or early 2026. Given that HPV16-positive head and neck cancer is projected to become the most prevalent type of head and neck cancer in the United States and Europe by the mid-2030s, successful trial outcomes, regulatory approval, and market launch of PDS0101 would be a major revenue driver.
2. Progression and Potential Future Commercialization of PDS01ADC in Metastatic Colorectal Cancer: PDS Biotechnology is advancing PDS01ADC, an IL-12 fused antibody-drug conjugate, in a Phase 2 clinical trial for metastatic colorectal cancer in collaboration with the National Cancer Institute (NCI). The colorectal cancer cohort of this trial met criteria for expansion to Stage 2 following positive Stage 1 results, and patient recruitment for this cohort is expected to be completed by the fourth quarter of 2025. Successful development and eventual market entry of PDS01ADC would contribute to future revenue.
3. Expansion of the Pipeline through Earlier-Stage Programs: While likely beyond the immediate 2-3 year revenue-generating horizon, the continued preclinical progress of the Infectimune-based universal flu vaccine and the FDA clearance of an Investigational New Drug (IND) application for Versamune MUC1 (also in collaboration with the NCI for metastatic colorectal cancer) represent crucial long-term drivers. Positive developments in these earlier-stage programs could lead to future clinical trials and eventual product launches, diversifying PDSB's potential revenue streams.

Share Issuance

• PDS Biotechnology filed an S-3 shelf registration to offer up to $200.0 million of securities, which includes a sales agreement for up to $20.0 million of common stock under an Amended and Restated At Market Issuance Sales Agreement dated August 13, 2024.
• In early 2025, the company completed financings, including a February offering that generated net proceeds of approximately $10.05 million.
• A registered direct offering in February 2025 resulted in expected gross proceeds of approximately $11 million upfront, with potential for an additional $11 million upon full cash exercise of associated warrants, with net proceeds intended for research and development and general corporate purposes.

Inbound Investments

• In early 2025, a securities purchase agreement raised $20.0 million, including $22.22 million principal debentures, primarily used to retire prior debt. These debentures carry an effective annual interest rate of approximately 24.1% and include restrictive covenants.
• The February 2025 registered direct offering involved participation from new and existing healthcare-focused institutional investors, as well as certain directors.
• EMV Capital plc, a deeptech and life sciences VC investment group, reported a 2.8% direct holding in PDS Biotechnology following its participation in the February 2025 registered direct offering.

Capital Expenditures

• As a clinical-stage biotechnology company, PDS Biotechnology's primary capital expenditures are focused on research and development (R&D).
• Research and development expenses for the first six months of 2025 were $10.04 million, compared to $11.23 million for the same period in 2024.
• The net proceeds from the February 2025 registered direct offering were intended for research and development expenses and general corporate purposes.